Merck KGaA hedged its Erbitux

Article Abstract:

Merck KGAA of Germany announced it has a previous licensing agreement with Yeda Research and Development of Israel to produce and market Erbitux. The German pharmaceutical giant also has an agreement with IMClone Systems Inc. of the United States to market the drug outside of the United States. Yeda Research and Development was recently awarded full patent rights for developing the colorectal drug Erbitux.

Contracts & orders received, Drugs, Alliances, partnerships, Patents & copyrights, Licensing/Sales Agreements, Contracts & orders let, Israel, Contracts, Biological products industry, Licensing agreements, Intellectual property, Company licensing agreement, Contract agreement, Yeda Research and Development, Erbitux (Medication)

---

Novartis to focus on influence insurers wield over doctors

Article Abstract:

Swiss pharmaceutical firm Novartis AG will eliminate 2,500 positions, 2.5% of its worldwide work force, to decrease management and administration expenses and lower pretax costs by $1.6 bil annually beginning in 2010. The move also reflects the powerful influence of health insurance companies in the prescribing of medicines.

Financial management, Personnel administration, Finance, Switzerland, Novartis AG, Company financing, NVTSY, Downsizing

---

Merck KGaA draws bidders for generics

Article Abstract:

Merck KGAA of Germany has its generic drug unit on the block as the pharmaceutical giant consolidates. International generics businesses are tabling offers that range from $5 billion to $6.5 billion.

Acquisitions & mergers, CHEMICALS AND ALLIED PRODUCTS, Parent-to-subsidiary activities, Subsidiary-to-parent activities, Mergers, acquisitions and divestments, Company acquisition/merger, Chemical industry, Pesticides industry, Herbicides, Sulphur industry, Subsidiaries, divisions and units, Financial report

Similar abstracts:

• Abstracts: Mercedes retools E-Class. Scania rejects bid from MAN. Europe car registrations rise for BMW, Daimler
• Abstracts: In Brazil, thicket of red tape spoils recipe for growth. Votorantim mines for growth. Naspers buys 30% stake in Brazilian rival Abril
• Abstracts: L'Oreal net gets new-markets lift. Luxottica's Oakley deal indicates drive for sporty
• Abstracts: Exxon loses U.K. ruling in fight with Venezuela. Santos draws deal talk amid review of cap. Probes of BP point to hurdles U.S. cases face; in commodities markets, trading on inside insight can be legal; price manipulation is fine line
• Abstracts: Loans snare poor divers. Tough year for Brittany PO. High seas netters back in North Pacific

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.